IP Library › Granted Patent US 12709614
Granted Patent B2
US 12709614 · App. 19/271,548 · Granted Aug 18, 2026

GLP-1R agonist and therapeutic method thereof

Inventors: Bin Liang (Hong Kong, CN); Jinzi Jason Wu (Hong Kong, CN); Bailing Yang (Hong Kong, CN)
Assignee: ASCLETIS PHARMA (CHINA) CO., LIMITED
C07D471/04A61K31/437C07D519/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12709614
App. No.
19/271,548
Granted
Aug 18, 2026
Kind
B2
Abstract

The present disclosure describes GLP-1R modulating compounds that are useful for treating GLP-1R-mediated diseases or conditions,

Claims (15)

1 . A method for treating a GLP-1R-mediated disease or condition, comprising administering to a subject in need thereof a therapeutically effective amount of compound 1,

or a pharmaceutically acceptable salt thereof;

wherein the GLP-1R-mediated disease or condition is selected from the group consisting of T1D (type 1 diabetes), T2DM (type 2 diabetes mellitus), hyperglycemia, weight management, chronic weight management, obesity, NAFLD (non-alcoholic fatty liver disease), NASH (non-alcoholic steatohepatitis), Parkinson's disease and hypertension.

2 . The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of a sodium salt, a calcium salt, a potassium salt, a magnesium salt and a lithium salt.

3 . The method of claim 1 , wherein the pharmaceutically acceptable salt is selected from the group consisting of

4 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is T1D (type 1 diabetes).

5 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is T2DM (type 2 diabetes mellitus).

6 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is hyperglycemia.

7 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is weight management.

8 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is chronic weight management.

9 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is obesity.

10 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is NAFLD (non-alcoholic fatty liver disease).

11 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is NASH (non-alcoholic steatohepatitis).

12 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is Parkinson's disease.

13 . The method of claim 1 , wherein the GLP-1R-mediated disease or condition is hypertension.